Hepatorenal syndrome: From physiopathology to treatment;Syndrome hépatorénal: De la physiopathologie au traitement

Annales Francaises d'Anesthesie et de Reanimation

Volumn 22, Issue 1, 2003, Pages 30-38

  Aguillon, D ^a   Seguin, P ^a   Malledant Y ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Ascite; Cirrhosis; Hepatorenal syndrome; Portal hypertension

Indexed keywords

ACETYLCYSTEINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; GLYPRESSINE; MISOPROSTOL; OCTREOTIDE; ORNIPRESSIN; PROSTAGLANDIN E2; SANDOSTATINE; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN;

ASCITES; HEPATORENAL SYNDROME; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDLINE; PATHOPHYSIOLOGY; POROSITY; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; RENOVASCULAR DISEASE; REVIEW; SPLANCHNIC BLOOD FLOW;

EID: 0345352787     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0750-7658(02)00851-1     Document Type: Short Survey

References (64)

1. Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascitis. Gastroenterology 1993;105:229-36.
2. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995;59:361-5.
3. Jeyarajah DR, Gonwa TA, McBride M, Testa G, Abbasoglu O, Husberg BS, et al. Hepatorenal syndrome: Combined liver kidney transplants versus isolated liver transplant. Transplantation 1997;64:1760-5.
4. Fernandez-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodriguez-Eire JL, et al. Systemic and regional hemodynamics in patients with liver failure and ascites with and without functional renal failure. Gastroenterology 1989;97:1304-12.
5. Maroto A, Ginès P, Arroyo V, Ginès A, Saló J, Clària J, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993;17:788-93.
6. Guevara M, Bru C, Ginès P, Fernández-Esparrach G, Sort P, Bataller R, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology 1998;28:39-44.
7. Kawakami M, Koda M, Murawaki Y, Kawasaki H, Ikawa S. Cerebral vascular resistance assessed by transcranial color Doppler ultrasonography in patients with chronic liver diseases. J Gastroenterol Hepatol 2001;16:890-7.
8. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;40:664-70.
9. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H. et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95.
10. Sugita S, Ohnishi K, Saito M, Okuda K. Splanchnic hemodynamics in portal hypertensive dogs with portal fibrosis. Am J Physiol 1987;252:G748-54.
11. Sato S, Ohnishi K, Sugita S, Okuda K. Splenic artery and superior mesenteric artery blood flow: nonsurgical Doppler US measurement in healthy subjects and patients with chronic liver disease. Radiology 1987;164:347-52.
12. Bosch J, Garcia-Pagán JC. Complications of cirrhosis. I, Portal hypertension. J Hepatol 2000;32(Suppl 1):141-56.
13. Martin PY, Ginès P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
14. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993;18:1139-43.
15. Niederberger M, Martin PY, Ginès P, Morris K, Tsai P, Xu DL, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109:1624-30.
16. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann R. Thalidomide inhibits tumor necrosis factor a decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996;23:1616-21.
17. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-7.
18. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of the sympathetic nervous system. Semin Liv Dis 1994;14:35-43.
19. Bernardi M, Trevisani F, Gasbarrini A, Gasbarrini G. Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liv Dis 1994:23-34.
20. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensine II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000;118:565-72.
21. 1 -vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991;100:494-501.
22. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992;327:1774-8.
23. Soper CPR, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996;347:1842-3.
24. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
25. Hampel H, Bynum GD, Zamora E, El-Serag HB. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am J Gastroenterol 2001;96:2206-10.
26. Ginès P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1997;93:234-41.
27. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501.
28. Navasa M, Follo A, Filella X, Jiménez W, Francitorra A, Planas R, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32.
29. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9.
30. Ruiz-del-Arbol L, Monescillo A, Jiménez W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-86.
31. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-110.
32. Afessa B, Kublis PS. Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterology 2000;95:484-9.
33. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27:1207-12.
34. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infection in cirrhotic patients with gastrointestinal bleeding: a meta analysis. Hepatology 1999;29:1655-61.
35. Kellerman PS. Perioperative care of the renal patient. Arch Intern Med 1994;154:1674-88.
36. Bird GLA, Sheron N, Goka AKJ, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112:917-20.
37. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifyline improves short-term survival in severe acute alcoholic hepatitis: a double blind, placebo-controlled trial. Gastroenterology 2000;119:11637-48.
38. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-30.
39. Guevara M, Ginès P, Fernández-Esparrach G, Sort P, Salmerón JM, Jiménez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
40. Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. Acta Gastroenterol Belg 2001;64:15-9.
41. Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8.
42. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P. Merenda R, et al. Reversal of type1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
43. Wilkes MM, Navickis RJ. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;135:149-64.
44. Cook D, Guyatt G. Colloid use for fluid resuscitation: evidence and spin. Ann Intern Med 2001;135:205-8.
45. Alderson P, Bunn F, Lefebvre C, Li Wan Po A, Roberts I, Schierhout G. The albumin Reviewers. Human albumin solution for resuscitation and volume expansion in critically ill patients (Cochrane Review). The Cochrane Library, 1. Oxford: Update Software; 2002.
46. Ginès P, Arroyo V. Is there still a need for albumin infusions to treat patients with liver disease? Gut 2000;46:588-90.
47. Lenz K, Hörtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis, Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991;101:1060-7.
48. Saló J, Ginès A, Quer JC, Fernández-Esparrach G, Guevara M, Ginès P, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatology 1996;25:916-23.
49. Le Moine O, El Nawar A, Jagodzinski R, Bourgeois N, Adler M, Gelin M, et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998;61:268-70.
50. Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig Dis Sci 1996;41:1054-6.
51. Duhamel C, Mauillon J, Berkelmas I, Bourienne A, Tranvouez JL. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propanolol and digitalic treatments: precipating and preventing factors? Am J Gastroenterol 2000;95:2984-5.
52. Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70.
53. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, et al. Terlipressin in patients with cirrhosis and typel hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30.
54. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an a-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998;28:937-43.
55. Durkin RJ, Winter SM. Reversal of hepatorenal syndrome with the combination norepinephrine and dopamine. Crit Care Med 1995;23:202-4.
56. Kaffy F, Borderie C, Chagneau C, Ripault MP, Larzillière I, Silvain C, et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patient. J Hepatology 1999;30:174.
57. Bennett WM, Keeffe E, Melnyk C, Mahler D, Rösch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975;135:964-71.
58. Rimola A, Ginès P, Arroyo V, Camps J, Perez-Ayuso RM, Quintero E, et al. Urinary excretion of 6-keto-prostaglandin F1 alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. Relationship to functional renal failure (hepatorenal syndrome). J Hepatol 1986;3:111-7.
59. 1 analogue) and albumin administration. J Hepatol 1990;11:153-8.
60. 2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure. J Hepatol 1993;17:220-6.
61. Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-5.
62. Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997;349:697-8.
63. Guevara M, Ginès P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22.
64. Mitzer SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective randomized, controlled clinical trial. Liv Transplant 2000;6:277-86.